MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease

Journal of Neuroimaging

Volumn 25, Issue 2, 2015, Pages 269-274

  Zhang, Bing ^a,b   Ferman, Tanis J ^c   Boeve, Bradley F ^a   Smith, Glenn E ^a   Maroney Smith, Mandie ^a   Spychalla, Anthony J ^a   Knopman, David S ^a   Jack, Clifford R ^a   Petersen, Ronald C ^a   Kantarci, Kejal ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Dementia with lewy bodies (DLB); Magnetic resonance spectroscopy (MRS); Mild cognitive impairment (MCI); MRI

Indexed keywords

CREATINE; N ACETYLASPARTIC ACID; ASPARTIC ACID; BIOLOGICAL MARKER; N-ACETYLASPARTATE;

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; INSTITUTIONAL REVIEW; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; N ACETYLASPARTIC ACID CREATINE RATIO; NERVOUS SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE SCANNER; POSTERIOR CINGULATE; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; ANALOGS AND DERIVATIVES; COGNITIVE DYSFUNCTION; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; LEWY BODY DISEASE; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; ASPARTIC ACID; BIOMARKERS; COGNITIVE DYSFUNCTION; CREATINE; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84924624460     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/jon.12138     Document Type: Article

References (46)

1. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447-1455.
2. Knopman DS. Alzheimer disease biomarkers and insights into mild cognitive impairment. Neurology 2013;80:978-980.
3. Morris JC. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol 2012;69:700-708.
4. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
5. Ferman T, Smith G, Pankratz V, et al. Non-amnestic mild cognitive impairment progresses to dementia with Lewy Bodies. American Academy of Neurology 65th Annual Meeting, Mar 16-23, 2013, San Diego, CA.
6. Fujishiro H, Nakamura S, Kitazawa M, et al. Early detection of dementia with Lewy bodies in patients with amnestic mild cognitive impairment using 123I-MIBG cardiac scintigraphy. J Neurol Sci 2012;315:115-119.
7. Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010;133:540-556.
8. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765-775.
9. Jack CR Jr, Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 2012;69:856-867.
10. Boeve BF. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010;1184:15-54.
11. Boeve BF. Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S41-S44.
12. Kantarci K. Proton MRS in mild cognitive impairment. J Magn Reson Imaging 2013;37:770-777.
13. Kantarci K, Weigand SD, Petersen RC, et al. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007;28:1330-1339.
14. Minoshima S, Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358-365.
15. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
16. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
18. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-750.
19. Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the UNIFIED Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
20. American Academy of Sleep Medicine. International Classification of Sleep Disorders 2: Diagnostic and Coding Manual. 2005, Chicago.
21. Benarroch EE. N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 2008;70:1353-1357.
22. Kantarci K, Petersen RC, Boeve BF, et al. 1H MR spectroscopy in common dementias. Neurology 2004;63:1393-1398.
23. Gomez-Isla T, Growdon WB, McNamara M, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003-2009.
24. Yokota O, Tsuchiya K, Uchihara T, et al. Lewy body variant of Alzheimer's disease or cerebral type lewy body disease? Two autopsy cases of presenile onset with minimal involvement of the brainstem. Neuropathology 2007;27:21-35.
25. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
26. Ferman TJ, Smith GE, Boeve BF, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol 2006;20:623-636.
27. Mori E, Shimomura T, Fujimori M, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol 2000;57:489-493.
28. Fayed N, Davila J, Oliveros A, et al. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol 2008;15:1089-1098.
29. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009;50:1638-1645.
30. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurology 1997;42:85-94.
31. Kantarci K, Senjem ML, Lowe VJ, et al. Effects of age on the glucose metabolic changes in mild cognitive impairment. Am J Neuroradiol 2010;31:1247-1253.
32. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-2340.
33. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
34. Kantarci K, Lowe V, Przybelski SA, et al. Magnetic resonance spectroscopy, beta-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology 2011;77:951-958.
35. Kantarci K, Jack CR Jr, Xu YC, et al.Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000;55:210-217.
36. Kantarci K, Weigand S, Przybelski S, et al. MRI and MRS Predictors of Mild Cognitive Impairment in a Population-based Sample. Neurology 2013;81:1-8.
37. Kantarci K, Weigand SD, Przybelski SA, et al. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 2009;72:1519-1525.
38. Kantarci K, Yang C, Schneider JA, et al. Antemortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012;33:878-885.
39. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
40. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain beta-amyloid load approaches a plateau. Neurology 2013;80:890-896.
41. Stavitsky K, Brickman AM, et al. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2006;63:1450-1456.
42. Ala TA, Yang KH, Sung JH, et al. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997;62:16-21.
43. Pasquier J, Michel BF, Brenot-Rossi I, et al. Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2002;29:1342-1348.
44. Fujishiro H, Iseki E, Kasanuki K, et al. Glucose hypometabolism in primary visual cortex is commonly associated with clinical features of dementia with Lewy bodies regardless of cognitive conditions. Int J Geriatr Psychiatry 2012;27:1138-1146.
45. Graff-Radford J, Boeve BF, Murray ME, et al. Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol Aging 2014;35(6):1483-1490.
46. Graff-Radford J, Boeve BF, Pedraza O, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 2012;135:2470-2477.